Glioblastoma metastases: a literature review and a description of six clinical observations

Goryaynov, S A; Потапов, А А; Ignatenko, M A; Zhukov, V Yu; Protskiy, S V; Zakharova, N. A.; Охлопков, В. А.; Shishkina, L V

doi:10.17116/neiro201579233-43

Cited by 5 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other very recent preliminary case reports have also supported this hypothesis, given that recurrent distal lesions are noted adjacent to ventricles, even if the primary tumor was remote from the ventricular margin [9]. CSF flow dynamics may account for accumulation of tumor cells in the fourth ventricle, or may create an optimal environment for implantation in this region.…”

Section: Discussionmentioning

confidence: 78%

Fourth Ventricular Lesions in Metastatic Gliomas: A Rare Predilection?

Khan

Poulin

Essig

2017

Brain Tumor Res Treat

View full text Add to dashboard Cite

Over the course of five years, a total of ten cases were collected of glioma patients in whom a distant lesion at the fourth ventricle was noted. A ‘distant lesion’ was defined as a lesion with a normal appearing tissue bridge at imaging between the primary and secondary locations. Previous imaging of these patients was reviewed along with clinical history, course of therapy, and available histology. A review of the literature was performed with respect to present knowledge on patterns of glioma proliferation and dissemination. This case series is the first to describe the fourth ventricle as a location that may be prone to secondary lesions in glioma patients. Further investigation on this subject may yield deeper insights into the mechanisms by which glial tumors spread within the brain, with the hope of developing or improving therapeutic targets.

show abstract

Section: Discussionmentioning

confidence: 78%

Fourth Ventricular Lesions in Metastatic Gliomas: A Rare Predilection?

Khan

Poulin

Essig

2017

Brain Tumor Res Treat

View full text Add to dashboard Cite

show abstract

“…Judging by the imaging changes of the primary thalamic tumor in this patient, the cause of death was not the recurrence and enlargement of the primary thalamic tumor, but the metastatic spread throughout the CNS, especially the brainstem and cervical spinal cord metastases. These may have affected the patient's breathing and lead to death due to dyspnea (8). Despite the combination of potentially effective targeted drug therapies after the second surgical resection of the intraspinal metastases, the patient was not able to tolerate the side effects of multiple drugs, resulting in poor evaluation of the efficacy of these drugs.…”

Section: Discussionmentioning

confidence: 99%

Multiple subtentorial metastasis in diffuse midline glioma receiving tumor treating fields: a case report and literature review

et al. 2021

View full text Add to dashboard Cite

Diffuse midline glioma (DMG) is one of fatal glioblastoma multiforme (GBM) with no proven medical therapies. Tumor treating fields (TTFields) is a new revolutionary therapy for GBM which prolongs the overall survival time obviously. However, we can observe more tumor growth phenomena (such as distant multiple metastases) than before. This report describes an adult patient who presented headache and dizziness, accompanied by left limb weakness, nausea, and vomiting following car accident trauma, following imaging examinations suggested thalamus GBM. He was treated with subtotal excision. Final pathology was diagnosed as DMG with H3F3A mutation, isocitrate dehydrogenase (IDH) wild type. Following concurrent chemoradiation therapy (CCRT) and adjuvant temozolomide (TMZ) chemotherapy + TTFields therapy were carried out. Supratentorial tumor has been exhibited a partial radiological response for nine months until TTFields was used irregularly or even discontinued in the later stage. Especially, subtentorial and spinal multiple metastasis occurred during this time. Both supratentorial and subtentorial tumors were treated with surgery, radiotherapy, chemotherapy, even targeted drugs, with the only difference being TTFields, but we could see different consequences for tumor growth. One conclusion might be drawn that TTFields can provide a longer survival time (14 vs. 8 months reported before) for DMG patients and improve survival benefits. However, we can observe that patients maybe die from subtentorial metastasis because TTFields could not cover the subtentorial tumors, which is the focal challenge at present. So further research on subtentorial tumors with TTFields is urgently needed.

show abstract

“…Additionally, meningeal, and pituitary cells are also part of the CNS [4]. When cells have genetic and/or epigenetic alterations, mechanisms such as replication, repair, and senescence are modified, resulting in an uncontrolled proliferation of cells with aggressive characteristics that allow them to invade neighboring tissues and sometimes give rise to metastasis, even in isolated and immune privileged sites such as the brain parenchyma [5]. Tumors originating from astrocytes are called astrocytomas; tumors from oligodendrocytes are oligodendrogliomas; and tumors from ependymal cells are called ependymomas.…”

Section: Introductionmentioning

confidence: 99%

Mutations in the PIK3C2B, ERBB3, KIT, and MLH1 Genes and their Relationship with Resistance to Temozolomide in Patients with High-grade Gliomas

Gómez¹,

Martínez²,

Flórez³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background. The treatment for patients with high-grade gliomas includes radiation therapy and temozolomide. However, some patients do not respond to temozolomide because they have a methylation reversal mechanism through the enzyme O6-methylguanine-DNA-methyltransferase. This biomarker has been used as a prognostic factor in patients receiving treatment with temozolomide. However, not all patients respond in the same way, which suggests the existence of other genes involved in resistance to temozolomide. Materials and Methods. A group of 31 patients with high-grade gliomas was recruited and were clinically, image pattern, and pathologically characterized. The sequencing of 324 genes related to different types of cancer was performed to detect mutations. Subsequently, a statistical analysis was conducted to determine the mutated genes that were most related to resistance to treatment. Results. The genes related to the second relapse of patients with high-grade glioma after the use of temozolomide according to Stupp protocol and metronomic dose were PIK3C2B, KIT, ERBB3, and MLH1. Conclusions. Considering the results obtained, we suggest that the mutations in the four genes and the methylation of the gene promoter that codes for MGMT protein could be related to the clinical evolution of patients with high-grade gliomas and its response to treatment with temozolomide.

show abstract

Glioblastoma metastases: a literature review and a description of six clinical observations

Cited by 5 publications

References 43 publications

Fourth Ventricular Lesions in Metastatic Gliomas: A Rare Predilection?

Fourth Ventricular Lesions in Metastatic Gliomas: A Rare Predilection?

Multiple subtentorial metastasis in diffuse midline glioma receiving tumor treating fields: a case report and literature review

Mutations in the PIK3C2B, ERBB3, KIT, and MLH1 Genes and their Relationship with Resistance to Temozolomide in Patients with High-grade Gliomas

Contact Info

Product

Resources

About